Zeenews BureauIn what may be seen as a positive development, it has emerged that the anti-estrogen drug Aromasin reduces the risk of breast cancer recurrence by about one-third in postmenopausal women previously treated with tamoxifen. According to researchers, `Aromasin`, which has been approved by the FDA, obstructs the production of estrogen that is made outside of the ovaries. The drug is also believed to prevent malignancies in women who have a risk due to age, family history and abnormal biopsy results.
Will write my own book to tell the truth: Sonia
India, America `indispensable partners`: John Kerry
Hrithik upset with Rs 400 cr alimony rumours
Eating chicken could make you immune to antibiotics